Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors

Medical and Pediatric Oncology

Volumn 35, Issue 6, 2000, Pages 719-723

  Park, Julie R ^a,b,e   Slattery, John ^b   Gooley, Theodore ^b   Hawkins, Douglas ^a,b   Lindsley, Karen ^a   Villablanca, Judith G ^c   Matthay, Katherine K ^d   Sanders, Jean E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

High grade glioma; High risk neuroblastoma; Pediatric solid tumors; Topotecan preparative regimen

Indexed keywords

TOPOTECAN;

AREA UNDER THE CURVE; CANCER GRADING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG TOLERABILITY; GLIOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; GLIOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; TOPOTECAN;

EID: 0033659372     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(20001201)35:6<719::AID-MPO52>3.0.CO;2-V     Document Type: Conference Paper

References (27)

1. Localized but unresectable neuroblastoma: Treatment and outcome of 145 cases
2. Consolidation chemotherapy and autologous bone marrow transplantation vs. continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies
3. The effectiveness of chemotherapy for treatment of high-grade astrocytomas in children: Results of a randomized trial
4. The Third Intergroup Rhabdomyosarcoma Study
5. Relapses of localized Ewing's sarcoma: Prognosis and outcome
6. The child with recurrent solid tumor
7. Surveillance scanning of children with medulloblastoma
8. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors
9. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT Solid Tumor Registry
10. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
11. Evaluation of 9-dimethylaminomethyl-10-hydroxy camptothecin (topotecan) against xenografts derived from adult and childhood tumors
12. Phase I study of topotecan for pediatric patients with malignant solid tumors
13. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
14. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
15. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
16. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group study
17. A phase I trial of a fixed systemic exposure (AUC) of carboplatin with continuous infusion topotecan in pediatric solid tumors
18. Regimen-related toxicity in patients undergoing bone marrow transplantation
19. High-performance liquid chromatographic analysis of the new antitumor drug SK7F 104864-1 (NSC 609699) in plasma
20. Clinical pharmacodynamics of continuous infusion topotecan in children; systemic exposure predicts hematologic toxicity
21. Carboplatin in childhood brain tumors: A Children's Cancer Study Group Phase II trial
22. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly-diagnosed pediatric malignant gliomas
23. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
24. Local control with multimodality therapy for stage 4 neuroblastoma
25. Phase I and pharmacologic study of topotecan in patients with impaired renal function
26. Sequences of topotecan and cisplatin: Phase I pharmocologic and in vitro studies to examine sequence dependence